{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:44:20Z","timestamp":1771461860429,"version":"3.50.1"},"reference-count":40,"publisher":"Becaris Publishing Limited","issue":"11","funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Delayed diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) represents a missed opportunity for intervention. This study estimates the health benefits of timely diagnosis and treatment with tafamidis.\n            <jats:bold>Methods:<\/jats:bold>\n            A disease simulation model was developed to predict health outcomes under scenarios of timely and delayed diagnosis and treatment. Efficacy and quality of life (QoL) profiles were derived from the pivotal tafamidis trial and diagnostic delay durations from the literature.\n            <jats:bold>Results:<\/jats:bold>\n            Timely diagnosis and treatment were predicted to extend mean life expectancy by 5.46 and 7.76\u00a0years, relative to delayed diagnosis, for wild-type and hereditary ATTR-CM, respectively. Corresponding QALY gains were 4.50 and 6.22.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Timely diagnosis and treatment with tafamidis are predicted to significantly improve survival and\u00a0QoL for ATTR-CM patients.\n          <\/jats:p>","DOI":"10.2217\/cer-2021-0071","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T13:36:40Z","timestamp":1624023400000},"page":"927-938","source":"Crossref","is-referenced-by-count":18,"title":["Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy"],"prefix":"10.57264","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6209-4370","authenticated-orcid":false,"given":"Mark H","family":"Rozenbaum","sequence":"first","affiliation":[{"name":"Pfizer, Capelle a\/d IJssel, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Large","sequence":"additional","affiliation":[{"name":"Pfizer UK, Walton Oaks, KT20 7NS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Bhambri","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY 10017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Stewart","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT 06340, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7432-9165","authenticated-orcid":false,"given":"Robert","family":"Young","sequence":"additional","affiliation":[{"name":"HEOR Ltd, Cardiff, CF23 8RB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3663-0464","authenticated-orcid":false,"given":"Alexander van","family":"Doornewaard","sequence":"additional","affiliation":[{"name":"HEOR Ltd, Cardiff, CF23 8RB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Dasgupta","sequence":"additional","affiliation":[{"name":"Indiana University, Indianapolis, IN 46202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University, Portland, OR 97239, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Nativi-Nicolau","sequence":"additional","affiliation":[{"name":"University of Utah, Salt Lake City, UT 84132, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"22","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg FL","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. JACC 73(22), 2872\u20132891 (2019).","journal-title":"JACC"},{"issue":"9","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer MS","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ. Heart Fail. 12(9), e006075 (2019).","journal-title":"Circ. Heart Fail."},{"issue":"30","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore JD","year":"2017","unstructured":"Gillmore JD, Damy T, Fontana M A new staging system for cardiac transthyretin amyloidosis. Eur. Heart J. 39(30), 2799\u20132806 (2017).","journal-title":"Eur. Heart J."},{"issue":"2","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer MS","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). JACC 68(2), 161\u2013172 (2016).","journal-title":"JACC"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40119-020-00205-3","article-title":"Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis","volume":"10","author":"Kroi F","year":"2021","unstructured":"Kroi F, Fischer N, Gezin A, Hashim M, Rozenbaum MH. Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. Cardiol. Ther. 10, 41\u201355 (2021).","journal-title":"Cardiol. Ther."},{"issue":"8","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles RM","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 7(8), 709\u2013716 (2019).","journal-title":"JACC Heart Fail."},{"issue":"3","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14\u2013333 African\u2013Americans","volume":"22","author":"Jacobson DR","year":"2015","unstructured":"Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14\u2013333 African\u2013Americans. Amyloid 22(3), 171\u2013174 (2015).","journal-title":"Amyloid"},{"issue":"1","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly Black Americans","volume":"372","author":"Quarta CC","year":"2014","unstructured":"Quarta CC, Buxbaum JN, Shah AM The amyloidogenic V122I transthyretin variant in elderly Black Americans. N. Engl. J. Med. 372(1), 21\u201329 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cardfail.2016.10.008","article-title":"Transthyretin cardiac amyloidosis in older Americans","volume":"22","author":"Brunjes DL","year":"2016","unstructured":"Brunjes DL, Castano A, Clemons A, Rubin J, Maurer MS. Transthyretin cardiac amyloidosis in older Americans. J. Card. Fail. 22(12), 996\u20131003 (2016).","journal-title":"J. Card. Fail."},{"issue":"1","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10741-016-9581-4","article-title":"Symptom burden in heart failure: assessment, impact on outcomes, and management","volume":"22","author":"Alpert CM","year":"2017","unstructured":"Alpert CM, Smith MA, Hummel SL, Hummel EK. Symptom burden in heart failure: assessment, impact on outcomes, and management. Heart Fail. Rev. 22(1), 25\u201339 (2017).","journal-title":"Heart Fail. Rev."},{"issue":"2","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi C","year":"2015","unstructured":"Rapezzi C, Lorenzini M, Longhi S Cardiac amyloidosis: the great pretender. Heart Fail. Rev. 20(2), 117\u2013124 (2015).","journal-title":"Heart Fail. Rev."},{"issue":"1","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane T","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140(1), 16\u201326 (2019).","journal-title":"Circulation"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review","volume":"10","author":"Rozenbaum MH","year":"2021","unstructured":"Rozenbaum MH, Large Samuel, Bhambri Rahul Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol. Ther. 10, 141\u2013159 (2021).","journal-title":"Cardiol. Ther."},{"issue":"12","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/eurheartj\/ehy697","article-title":"Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?","volume":"40","author":"Falk RH","year":"2019","unstructured":"Falk RH. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end? Eur. Heart J. 40(12), 1009\u20131012 (2019).","journal-title":"Eur. Heart J."},{"issue":"24","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore JD","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24), 2404\u20132412 (2016).","journal-title":"Circulation"},{"issue":"12","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.amjmed.2015.05.039","article-title":"Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology","volume":"128","author":"Maurer MS","year":"2015","unstructured":"Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am. J. Med. 128(12), 1275\u20131280 (2015).","journal-title":"Am. J. Med."},{"issue":"2","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","article-title":"Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies","volume":"9","author":"Koike H","year":"2020","unstructured":"Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol. Ther. 9(2), 317\u2013333 (2020).","journal-title":"Neurol. Ther."},{"key":"e_1_3_4_20_2","unstructured":"ASNC Practice Points: 99mTechnetium-Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis (2018). www.asnc.org\/content.asp?contentid=290"},{"issue":"2","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-Diagnostic criteria and appropriate utilization","volume":"27","author":"Dorbala S","year":"2020","unstructured":"Dorbala S, Ando Y, Bokhari S ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-Diagnostic criteria and appropriate utilization. J. Nucl. Cardiol. 27(2), 659\u2013673 (2020).","journal-title":"J. Nucl. Cardiol."},{"issue":"10","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.cardfail.2020.09.239","article-title":"Temporal trends of wild-type Attr amyloidosis in the Transthyretin Amyloidosis Outcomes Survey","volume":"26","author":"Nativi-Nicolau J","year":"2020","unstructured":"Nativi-Nicolau J, Siu A, Dispenzieri A Temporal trends of wild-type Attr amyloidosis in the Transthyretin Amyloidosis Outcomes Survey. J. Card. Fail. 26(10), S82 (2020).","journal-title":"J. Card. Fail."},{"key":"e_1_3_4_23_2","volume-title":"XVIth International Symposium on Amyloidosis; 2018 March 26\u201329","author":"Lousada I","year":"2018","unstructured":"Lousada I, Maurer M, Warner M, Guthrie S, Hsu K, Grogan M. Amyloidosis research consortium cardiac amyloidosis survey: results from patients with AL and ATTR amyloidosis and their caregivers. Presented at: XVIth International Symposium on Amyloidosis; 2018 March 26\u201329 Kumamoto, Japan (2018)."},{"key":"e_1_3_4_24_2","unstructured":"European Medicines Agency. Assessment report: vyndaqel (2019). www.ema.europa.eu\/en\/documents\/variation-report\/vyndaqel-h-c-2294-x-0049-g-epar-assessment-report_en.pdf"},{"key":"e_1_3_4_25_2","unstructured":"US Food and Drug Administration. FDA approves new treatments for heart disease caused by a serious rare disease transthyretin mediated amyloidosis (2019). www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretin-mediated#:~:text=On%20May%203%2C%20the%20U.S. approved%20treatments%20for%20ATTR%2DCM"},{"issue":"11","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379(11), 1007\u20131016 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop E","year":"2018","unstructured":"Bishop E, Brown EE, Fajardo J, Barouch LA, Judge DP, Halushka MK. Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid 25(3), 174\u2013179 (2018).","journal-title":"Amyloid"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","article-title":"Diagnostic delay in wild type transthyretin cardiac amyloidosis \u2013 a clinical challenge","volume":"304","author":"Ladefoged B","year":"2020","unstructured":"Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis \u2013 a clinical challenge. Int. J. Cardiol. 304, 138\u2013143 (2020).","journal-title":"Int. J. Cardiol."},{"key":"e_1_3_4_29_2","unstructured":"TA267: ivabradine for treating chronic heart failure. National Institute for Health and Care Excellence (2012). www.nice.org.uk\/Guidance\/TA267"},{"key":"e_1_3_4_30_2","unstructured":"TA388: sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. National Institute for Health and Care Excellence (2016). www.nice.org.uk\/guidance\/ta388"},{"key":"e_1_3_4_31_2","unstructured":"Classes of Heart Failure (2017). American Heart Association. www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/classes-of-heart-failure"},{"issue":"15","key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jama.2011.1474","article-title":"National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998\u20132008","volume":"306","author":"Chen J","year":"2011","unstructured":"Chen J, Normand S-LT, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998\u20132008. JAMA 306(15), 1669\u20131678 (2011).","journal-title":"JAMA"},{"issue":"18","key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.jacc.2009.08.019","article-title":"Hospitalizations after heart failure diagnosis: a community perspective","volume":"54","author":"Dunlay SM","year":"2009","unstructured":"Dunlay SM, Redfield MM, Weston SA Hospitalizations after heart failure diagnosis: a community perspective. JACC 54(18), 1695\u20131702 (2009).","journal-title":"JACC"},{"issue":"8","key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18(8), 891\u2013975 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"e_1_3_4_35_2","unstructured":"Pfizer. ATTR-ACT data on file (2019)."},{"key":"e_1_3_4_36_2","unstructured":"Pfizer. ATTR-ACT extension study (Preliminary August 2019 database lock) data on file (2019)."},{"key":"e_1_3_4_37_2","article-title":"United States life tables: 2017","author":"Arias E","year":"2019","unstructured":"Arias E, Xu J. United States life tables: 2017. Centers for Disease Control and Prevention (2019).","journal-title":"Centers for Disease Control and Prevention"},{"issue":"3","key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw JW","year":"2005","unstructured":"Shaw JW, Johnson JA, Coons SJJMC. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med. Care 43(3), 203\u2013220 (2005).","journal-title":"Med. Care"},{"issue":"2","key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy T","year":"2020","unstructured":"Damy T, Garcia-Pavia P, Hanna M Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur. J. Heart Fail. 23(2), 277\u2013285 (2020).","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","article-title":"Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial","volume":"24","author":"Keohane D","year":"2017","unstructured":"Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid 24(1), 30\u201336 (2017).","journal-title":"Amyloid"},{"issue":"10","key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/13696998.2020.1789866","article-title":"Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark","volume":"23","author":"Pilgaard T","year":"2020","unstructured":"Pilgaard T, Pedersen MH, Poulsen SH. Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark. J. Med. Econ. 23(10), 1084\u20131091 (2020).","journal-title":"J. Med. Econ."},{"issue":"2","key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"ehaa946.2142","DOI":"10.1093\/ehjci\/ehaa946.2142","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"41","author":"Damy T","year":"2020","unstructured":"Damy T, Elliott P, Gundapaneni B Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Eur. Heart J. 41(Suppl. 2), ehaa946.2142 (2020).","journal-title":"Eur. Heart J."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2021-0071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:10:54Z","timestamp":1679231454000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2021-0071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.2217\/cer-2021-0071"],"URL":"https:\/\/doi.org\/10.2217\/cer-2021-0071","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}